

**19 June 2020**

## **Results of 2020 Annual Meeting of Stockholders**

**Minnesota, United States and Melbourne, Australia – 19 June 2020** – Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) held its Annual Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Annual Meeting and Proxy Statement dated 29 May 2020 were passed by way of a poll.

**This announcement has been approved by the President & Chief Executive Officer, Mike McCormick.**

### **Contact details:**

#### **Investor relations**

Leijie Li  
Vesparum Capital  
T: (61) 3 8582 4800  
[ospreymed@vesparum.com](mailto:ospreymed@vesparum.com)

#### **Company**

Brendan Case  
Company Secretary  
M: (61) 410 442 393  
[brendan@casegovernance.com.au](mailto:brendan@casegovernance.com.au)

### **About Osprey Medical (ASX: OSP)**

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### **Foreign Ownership Restriction**

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



ANNUAL MEETING (COMMON STOCK)  
Friday, 19 June, 2020

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1A	RE-ELECTION OF MR JOHN ERB AS A CLASS I DIRECTOR	N	449,013,905 99.80%	0 0.00%	911,000 0.20%	721,674	449,924,905 100.00%	0 0.00%	721,674	Carried
1B	RE-ELECTION OF MR NEVILLE MITCHELL AS A CLASS I DIRECTOR	N	466,626,109 99.74%	0 0.00%	1,226,680 0.26%	921,674	467,852,789 100.00%	0 0.00%	921,674	Carried
2	APPROVAL OF 10% PLACEMENT FACILITY	N	465,865,222 99.56%	2,054,467 0.44%	25,000 0.01%	829,774	465,890,222 99.56%	2,054,467 0.44%	829,774	Carried
3	APPROVAL OF AMENDMENT TO 2016 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER	N	456,594,249 97.53%	11,539,565 2.46%	25,000 0.01%	615,649	456,619,249 97.54%	11,539,565 2.46%	615,649	Carried
4A	APPROVAL OF OPTION GRANTS TO MR JOHN ERB, THE CHAIRMAN AND A NON-EXECUTIVE DIRECTOR OF THE COMPANY, IN LIEU OF DIRECTORS FEES	N	457,253,374 97.67%	10,822,940 2.31%	75,000 0.02%	623,149	457,328,374 97.69%	10,822,940 2.31%	623,149	Carried
4B	APPROVAL OF OPTION GRANTS TO MR NEVILLE MITCHELL, A NON-EXECUTIVE DIRECTOR OF THE COMPANY, IN LIEU OF DIRECTORS FEES	N	457,253,374 97.67%	10,822,940 2.31%	75,000 0.02%	623,149	457,328,374 97.69%	10,822,940 2.31%	623,149	Carried
4C	APPROVAL OF OPTION GRANTS TO MS SANDRA LESENFANTS, A NON-EXECUTIVE DIRECTOR OF THE COMPANY, IN LIEU OF DIRECTORS FEES	N	457,253,374 97.67%	10,822,940 2.31%	75,000 0.02%	623,149	457,328,374 97.69%	10,822,940 2.31%	623,149	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item